Supernus Pharmaceuticals is a pharmaceutical company that specializes in developing and commercializing drugs for central nervous system disorders. The company was founded in 2005 and is headquartered in Rockville, Maryland. Supernus Pharmaceuticals has a portfolio of products that includes treatments for epilepsy, attention deficit hyperactivity disorder (ADHD), and other neurological conditions. The company's products are sold in the United States and other countries, and Supernus Pharmaceuticals has partnerships with other pharmaceutical companies to develop and market new drugs. Supernus Pharmaceuticals is publicly traded on the NASDAQ stock exchange under the ticker symbol SUPN.